# Phase 9 execution ownership and alternative review route

Date: 2026-10-18. Documentation-only assignment and review record.

## Operator assignment

The operator directed Codex to execute the remaining ownership and review-routing work and then explicitly assigned GPT-PM as product owner and signatory (“гпт пм владелец и подписант”). The distinction in `D:\Repo\AGENTS.md` remains in force: for this delegated task, the operator is accountable, Codex is the executor, and a role assignment does not invent an owning production service.

For the technical review deliverables, GPT-PM is the operator-designated product decision owner (and OQ-07 product signatory); Codex executes the task-local TR documentation, and an actual `architect` reviewer independently reviewed the contracts. The architect package contains recommendations, not adopted technical contract decisions. GPT-PM's OQ-07 product decision is NOT_RECORDED because the attempted PM Bridge request did not reach GPT-PM. OQ-14 and OQ-18 were not included in that request and their product decisions have not yet been routed or recorded. These assignments cover the current documentation deliverables only; they do not name a production service owner or assign future runtime maintenance.

GPT-PM is assigned as the product decision owner/signatory for OQ decisions and as the product-accountable owner for ensuring the ACS-100 ownership gap is resolved. Codex remains the technical author/executor, not the product decision owner. GPT-PM is not represented as a live alert receiver or as a medically qualified clinician. The project-wide delegation matrix reserves medical/clinical authority for a human; actual clinical numeric limits and symptom scope therefore remain unavailable for product use until an authorized qualified human signs them.

## Bounded alternative reviewer route

The named `product-owner` and `technical-writer` agent profiles are unavailable in the current host (`unknown agent_type`). The operator delegated the route choice to Codex. Codex approves and adopts this limited route in place of restoring those profiles:

| Available actual reviewer | Assigned scope | Does not substitute for |
|---|---|---|
| `architect` | TR contract review and technical consistency for OQ-07, OQ-14 and OQ-18 | Production service ownership, implementation/runtime evidence, GPT-PM product decisions or qualified clinical sign-off |
| `doc-updater` | Source accuracy, traceability, consistency and documentary completeness | Product acceptance, OQ policy decisions or safety signatures |
| `product-ux-reviewer` | User journey, story acceptance clarity and product-facing implications | Product-owner authority, final disposition of the 13 stories or clinical authority |

Every review is tied to a supplied or observed exact HEAD/tree and records its scope, findings and limitations. Reviewer-agent role labels are not people or service owners. Codex writes the technical/documentation package and handles follow-up remediation; the operator remains accountable for the delegated task. GPT-PM owns the product decisions by operator assignment. The 13 story dispositions remain PENDING under the operator's earlier direction.

## Reviews performed at the pre-change source revision

All three actual reviewer tasks were read-only at HEAD `42c2f0218422cda9c805d1bbf9702a61a54018ee`, tree `ec3769fdaf0e4cee56aba5b7b99ee4a65f386b7a`, using GPT-6 Luna / medium effort:

- `architect` reviewed the OQ technical package. It recommends a prescription-only ceiling with no clamping of valid performed-set facts and typed fail-closed outcomes for OQ-07; structured source-bound factual claims rendered through deterministic templates for OQ-14; and a versioned immutable composer snapshot, separate observed/projected volume, supported recovery horizon, candidate-only visual matches and idempotent plan persistence for OQ-18. This is technical review evidence, not a named service owner or a product/safety signature.
- `product-ux-reviewer` found the prior alternative route underspecified and confirmed that reviewer roles cannot accept stories, own a service or sign clinical values. It recommended the bounded route above and retaining the product/safety boundary.
- `doc-updater` confirmed the source documents were internally consistent but the alternative route lacked authority, evidence format and closure criteria. It recommended the same bounded route, exact-head records and preservation of the distinct ownership/signature boundaries.

These reviews describe the source revision before this record and the related acceptance-table update. Re-review the changed documents before treating this record as final reviewed documentation.

## GPT-PM signatory request and current evidence

The PM Bridge send-and-await request `8a1a6c41-4f21-4d0c-a44e-202610184201` (job `8c202a57-5fbe-417e-9980-c8f4a17318ef`) was prepared for GPT-PM with the OQ-07 technical direction, product-level fail-closed gate, operator assignment, alternative reviewer route and ACS-100 boundary. OQ-14 and OQ-18 were not in its scope. PM Bridge returned `ATTACHMENT_NOT_LANDED`, `sendPhase=not-started`, no `userTurnId`, and no `replyId`; nothing reached GPT-PM and no acknowledgment or signature exists for OQ-07. Retrying the same request with different inline content was rejected because the failed send-and-await lineage already owns the request ID; a separate `gpt_send` was also refused for the same reason. Do not treat the operator's role assignment as GPT-PM's acceptance or signature.

The PM Bridge decision `AICOACH-OQ07-SIGNATURE` is recorded as PENDING. Its recommendation is to accept the product-level fail-closed gate, while keeping actual medical/clinical limits and symptom scope unsigned until an authorized human signs them.

## ACS-100 ownership boundary

GPT-PM is assigned product accountability for ensuring ACS-100 is routed to an actual owner. The required alert recipient is the owning runtime service's real on-call rotation, with project operations/SRE as an escalation path only if that service has no rotation. Current inspected AI Coach sources contain proposed event/sink/alert design but no deployed AI Coach alerting service or named rotation. Assigning GPT-PM or Codex as the operational recipient would be false: neither is evidenced as a receiver of the alert events. ACS-100 therefore remains CARRIED until the runtime service and its operational ownership record identify a real recipient and alert delivery is proven.

## Current status and next actions

- **Assigned and executed:** GPT-PM is assigned product decision ownership/signatory; Codex owns execution of the technical-documentation tasks; the architect reviewer produced recommendations for OQ-07, OQ-14 and OQ-18. The bounded alternative reviewer route is approved and exercised on the pre-change source revision. **TR recommendation/package recorded; GPT-PM contract/product decisions NOT_RECORDED** for OQ-07, OQ-14 and OQ-18.
- **Assigned, awaiting acceptance/signature:** GPT-PM is the operator-designated product owner/signatory and product-accountable owner for the ACS-100 assignment. The PM Bridge request for OQ-07/ACS-100 did not send, so its role acknowledgment and OQ-07 product-level signature are NOT_RUN. OQ-14/18 decisions have not yet been separately routed or recorded.
- **Still requires a human:** a qualified clinical/safety authority must sign the actual OQ-07 numeric limits and symptom scope. GPT-PM's product signature cannot establish medical qualifications.
- **Still requires an operational service:** identify the AI Coach runtime service and its real on-call rotation for ACS-100; then configure and prove alert delivery.
- **Still pending by operator direction:** final acceptance or revision of all 13 story dispositions on the then-current acceptance-file revision.

No tests, checks, builds, CI, migrations, runtime actions, alert configuration, production changes, push or merge were performed for this documentation record.
